Neumirna Therapeutics ApS: Financial statements 2024
CVR: 41696451
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Neumirna Therapeutics ApS (CVR 41696451) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -5,495,935 and a net result of DKK -6,954,201 compared with DKK -8,034,417 the year before. Equity in the 2024 report amounted to DKK -18,422,153. The company had 5 employees in the financial year.
- Gross Profit
- DKK -5,495,935
- Profit/Loss
- DKK -6,954,201
- Equity
- DKK -18,422,153
- Total Assets
- DKK 5,506,595
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -5.5M | -7M | -18.4M | 5 |
| 2023 | - | -5.5M | -8M | -11.5M | 3 |
| 2022 | - | -4.7M | -5.3M | -3.4M | 3 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Neumirna Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -5,476,181, and the net result was DKK -8,034,417.
About Neumirna Therapeutics ApS
Neumirna Therapeutics ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ellen Kinson Donnelly. The board consists of Luis Garcia Pareras (chair), Andreas Wallnöfer, Ellen Kinson Donnelly and Francesco Paolo Di Giorgio. The company's owners include HELLERUNG ApS, INVIVO VENTURES III, FCRE and Innovestor Life Science Fund Ky. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK -53,859,865 and a net result of DKK -55,785,767 compared with DKK -6,954,201 the year before. Equity in the 2025 report amounted to DKK 91,816,175.